Comparison of Omicron and Delta Variants of SARS-CoV-2 : A Systematic Review of Current Evidence
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
INTRODUCTION: Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) caused the outbreak of coronavirus disease 2019 (COVID-19) in late 2019 in Wuhan, China. In early 2020, the disease spread rapidly around the world. Since the pandemic, SARS-CoV-2 has evolved dramatically into a wide variety of variants endowed with devastating properties. As of March 6, 2022, five SARS-CoV-2 variants of concern, including Alpha, Beta, Gamma, Delta, and Omicron strains have been identified. Due to the crucial importance of understanding the differences between the Omicron and Delta variants, this systematic review was conducted.
METHODS: This systematic review investigated new variants of Omicron SARS-CoV-2 based on cur-rent studies. Online databases were searched for English articles as of January 03, 2023. Selection of publications was a two-step process of title/abstract and full-text assessment against eligibility crite-ria. The relevant data from the included articles were systematically collected and organized in a designed table for analysis. To ensure the quality of the review, the PRISMA checklist and Newcas-tle-Ottawa Scale (NOS) of quality assessment were utilized.
RESULTS: The data extracted from 58 articles were analyzed, including 10003 pieces of evidence. Lower risk of hospitalization, ICU admission, and mortality after vaccination were reported in the Omicron variant compared to the Delta variant. Additionally, the Delta variant led to more severe clinical symptoms in comparison to the Omicron variant.
CONCLUSION: The Omicron variant of SARS-CoV-2 results in less severe disease outcomes as com-pared to Delta. Nevertheless, it remains crucial to maintain ongoing monitoring, implement contain-ment measures, and adapt vaccination protocols to effectively address the evolving variants.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Infectious disorders drug targets - (2024) vom: 05. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
SeyedAlinaghi, SeyedAhmad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 06.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0118715265279242240216114548 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369355229 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369355229 | ||
| 003 | DE-627 | ||
| 005 | 20240306233746.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240306s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0118715265279242240216114548 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM369355229 | ||
| 035 | |a (NLM)38445691 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a SeyedAlinaghi, SeyedAhmad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of Omicron and Delta Variants of SARS-CoV-2 |b A Systematic Review of Current Evidence |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a INTRODUCTION: Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) caused the outbreak of coronavirus disease 2019 (COVID-19) in late 2019 in Wuhan, China. In early 2020, the disease spread rapidly around the world. Since the pandemic, SARS-CoV-2 has evolved dramatically into a wide variety of variants endowed with devastating properties. As of March 6, 2022, five SARS-CoV-2 variants of concern, including Alpha, Beta, Gamma, Delta, and Omicron strains have been identified. Due to the crucial importance of understanding the differences between the Omicron and Delta variants, this systematic review was conducted | ||
| 520 | |a METHODS: This systematic review investigated new variants of Omicron SARS-CoV-2 based on cur-rent studies. Online databases were searched for English articles as of January 03, 2023. Selection of publications was a two-step process of title/abstract and full-text assessment against eligibility crite-ria. The relevant data from the included articles were systematically collected and organized in a designed table for analysis. To ensure the quality of the review, the PRISMA checklist and Newcas-tle-Ottawa Scale (NOS) of quality assessment were utilized | ||
| 520 | |a RESULTS: The data extracted from 58 articles were analyzed, including 10003 pieces of evidence. Lower risk of hospitalization, ICU admission, and mortality after vaccination were reported in the Omicron variant compared to the Delta variant. Additionally, the Delta variant led to more severe clinical symptoms in comparison to the Omicron variant | ||
| 520 | |a CONCLUSION: The Omicron variant of SARS-CoV-2 results in less severe disease outcomes as com-pared to Delta. Nevertheless, it remains crucial to maintain ongoing monitoring, implement contain-ment measures, and adapt vaccination protocols to effectively address the evolving variants | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Coronavirus disease 2019 | |
| 650 | 4 | |a Delta Variant | |
| 650 | 4 | |a Omicron new variant. | |
| 650 | 4 | |a Omicron subvariant | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Afsahi, Amir Masoud |e verfasserin |4 aut | |
| 700 | 1 | |a Mirzapour, Pegah |e verfasserin |4 aut | |
| 700 | 1 | |a Afzalian, Arian |e verfasserin |4 aut | |
| 700 | 1 | |a Shahidi, Ramin |e verfasserin |4 aut | |
| 700 | 1 | |a Dashti, Mohsen |e verfasserin |4 aut | |
| 700 | 1 | |a Ghasemzadeh, Afsaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Paranjkhoo, Parinaz |e verfasserin |4 aut | |
| 700 | 1 | |a Parsaei, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Pashaei, Ava |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammadi, Parsa |e verfasserin |4 aut | |
| 700 | 1 | |a Najafi, Mohammad Sadeq |e verfasserin |4 aut | |
| 700 | 1 | |a Mahrokhi, Sona |e verfasserin |4 aut | |
| 700 | 1 | |a Matini, Parisa |e verfasserin |4 aut | |
| 700 | 1 | |a Moradi, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Karimi, Amirali |e verfasserin |4 aut | |
| 700 | 1 | |a Afroughi, Solaiman |e verfasserin |4 aut | |
| 700 | 1 | |a Mehraeen, Esmaeil |e verfasserin |4 aut | |
| 700 | 1 | |a Dadras, Omid |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infectious disorders drug targets |d 2006 |g (2024) vom: 05. März |w (DE-627)NLM163628408 |x 2212-3989 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:05 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0118715265279242240216114548 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 05 |c 03 | ||